Document Detail

Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?
MedLine Citation:
PMID:  23114898     Owner:  NLM     Status:  In-Data-Review    
Atrial fibrillation is prevalent in dialysis patients. Both ischaemic and haemorrhagic stroke are common in patients on dialysis with atrial fibrillation. In the general population, warfarin is highly effective for prophylaxis of ischaemic stroke, and though warfarin use likely increases the risk of intracranial haemorrhage, the absolute increase in risk is small. In the general population, absolute and relative increases in major extracranial bleeding from warfarin use are also both modest. In patients on dialysis, the effectiveness of warfarin as a prophylaxis for ischaemic stroke and its effects on intracranial or extracranial bleeding have not been assessed in randomized trials. Cohort studies vary greatly in their estimates of the magnitude of the increased risk of bleeding from warfarin use. A single cohort study found rates of intracranial haemorrhage in patients on dialysis with atrial fibrillation to be in an order of magnitude that is greater than those in the general population with atrial fibrillation, and that intracranial haemorrhage more than doubled in association with warfarin use. Basic, translational and limited clinical observations also implicate warfarin in the pathogenesis of vascular calcification, which is likely on the causal pathway to patient-important vascular outcomes. Finally, the effect of warfarin on ischaemic stroke in three recent large observational studies has been in the direction of harm, no benefit, and modest, non-statistically significant benefit, respectively. We believe that no clear recommendation can be made between three alternative approaches. It is acceptable to withhold or discontinue warfarin in patients on dialysis, to offer anticoagulants to all dialysis patients without a contraindication whose congestive heart failure, hypertension, age, diabetes and previous stroke or transient ischaemic attack (CHADS(2)) score >1 or 2 and to discuss and individualize prophylaxis on a patient-by-patient basis. Randomized trials of new agents are needed in this area.
Catherine M Clase; Rachel M Holden; Manish M Sood; Claudio Rigatto; Louise M Moist; Benjamin K A Thomson; Johannes F E Mann; Deborah L Zimmerman
Related Documents :
11277948 - Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic...
281638 - Indomethacin-associated peptic ulceration.
16137998 - Perforated duodenal diverticulitis: a report of three cases.
21166848 - Glucose control and outcome in patients with stable diabetes and previous coronary, cer...
11591188 - An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis ass...
3976468 - Flail mitral valve syndrome: comparison with chronic mitral regurgitation of other etio...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  27     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-11-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  3719-24     Citation Subset:  IM    
Correspondence and offprint requests to: Catherine M. Clase; E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic oppor...
Next Document:  Is chronic hyponatremia a novel risk factor for hip fracture in the elderly?